Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
120.10
-0.74 (-0.61%)
Streaming Delayed Price
Updated: 2:48 PM EDT, Apr 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,049,080
Open
120.37
Bid (Size)
120.09 (100)
Ask (Size)
120.11 (100)
Prev. Close
120.84
Today's Range
119.22 - 121.65
52wk Range
73.31 - 125.14
Shares Outstanding
2,531,374,696
Dividend Yield
2.83%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Today 6:50 EDT
From
Merck & Co., Inc.
Via
Business Wire
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Today 6:45 EDT
From
Merck & Co., Inc.
Via
Business Wire
Performance
YTD
+12.8%
+12.8%
1 Month
-1.1%
-1.1%
3 Month
+14.1%
+14.1%
6 Month
+33.3%
+33.3%
1 Year
+37.9%
+37.9%
More News
Read More
The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future
April 01, 2026
Via
Finterra
Topics
Artificial Intelligence
Earnings
Economy
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
April 01, 2026
From
Merck & Co., Inc.
Via
Business Wire
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
March 31, 2026
Via
MarketMinute
Topics
Economy
Intellectual Property
Stocks
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
March 31, 2026
Via
Finterra
Topics
Initial Public Offering
Merck Just Made a Big Bet on a New Cancer Growth Engine
↗
March 31, 2026
Via
MarketBeat
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
March 30, 2026
From
Merck & Co., Inc.
Via
Business Wire
This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks
↗
March 30, 2026
Via
The Motley Fool
Topics
ETFs
Stocks
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
March 29, 2026
From
Merck & Co., Inc.
Via
Business Wire
1 Reason Eli Lilly Stock Is Still a Buy
↗
March 28, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
2 Healthcare Stocks That Could Soar Over the Next 5 Years
↗
March 26, 2026
Via
The Motley Fool
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
March 26, 2026
Via
MarketMinute
Topics
Intellectual Property
ARM Makes Its Move While Wall Street Watches the Strait
↗
March 26, 2026
Via
Chartmill
The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind
March 25, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
March 25, 2026
Via
Finterra
Topics
Initial Public Offering
Intellectual Property
World Trade
Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience
March 25, 2026
Via
Finterra
Topics
Artificial Intelligence
Economy
Intellectual Property
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
March 25, 2026
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
March 25, 2026
From
Merck & Co., Inc.
Via
Business Wire
1 S&P 500 Stock to Target This Week and 2 We Ignore
March 24, 2026
Via
StockStory
Topics
Stocks
Bristol-Myers Squibb Shares Jump 3.3% on Robust 2026 Guidance and High Dividend Yield
March 23, 2026
Via
MarketMinute
Topics
Economy
Initial Public Offering
Intellectual Property
Pfizer vs Moderna: Which Pharma Stock Has More Upside?
↗
March 19, 2026
Via
The Motley Fool
Topics
Intellectual Property
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
March 18, 2026
From
Merck & Co., Inc.
Via
Business Wire
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
March 18, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
The Grand Divergence: Finance Surges as Health Care Braces for a Historic Q1 Earnings Slump
March 17, 2026
Via
MarketMinute
Topics
Earnings
Economy
Initial Public Offering
Frequently Asked Questions
Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 120.10
When was Merck & Co last traded?
The last trade of Merck & Co was at 04/02/26 02:48 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 304.02B
How many shares of Merck & Co are outstanding?
Merck & Co has 304B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.